Enveric Biosciences (ENVB) Gross Margin (2014 - 2020)
Enveric Biosciences (ENVB) posted Gross Margin of 22.25% for Q3 2020, up 1.02% sequentially from 22.02% in Q2 2020, and up 149.0% YoY from 8.94% in Q4 2019.
Enveric Biosciences (ENVB) Gross Margin (2014 - 2020) Analysis & Trends
Enveric Biosciences has reported Gross Margin for 7 years, with the latest figure at 22.25% in Q3 2020.
- Quarterly Gross Margin rose 149.0% year-over-year to 22.25% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 20.66% (up 42.0% YoY) and the FY2019 annual result came in at 20.42%, down 47.0% from the prior year.
- Gross Margin rose to 22.25% in Q3 2020 per ENVB's latest filing, from 22.02% in the prior quarter.
- Over five years, Gross Margin peaked at 26.75% in Q1 2017 and troughed at 16.69% in Q4 2016.
- A 5-year average of 20.37% and a median of 20.46% in 2017 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2016 and 2017: Gross Margin slumped 2721 bps in 2016, then surged 885 bps in 2017.
- Over 5 years, Gross Margin stood at 16.69% in 2016, then grew by 7 bps to 17.81% in 2017, then rose by 4 bps to 18.53% in 2018, then grew by 3 bps to 19.08% in 2019, then advanced by 17 bps to 22.25% in 2020.
- According to Business Quant data, Gross Margin over the past three periods registered 22.25%, 22.02%, and 19.59% for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 22.25% |
| Jun 30, 2020 | 22.02% |
| Mar 31, 2020 | 19.59% |
| Dec 31, 2019 | 19.08% |
| Sep 30, 2019 | 20.76% |
| Jun 30, 2019 | 21.63% |
| Mar 31, 2019 | 20.03% |
| Dec 31, 2018 | 18.53% |
| Sep 30, 2018 | 22.18% |
| Jun 30, 2018 | 21.57% |
| Mar 31, 2018 | 21.18% |
| Dec 31, 2017 | 17.81% |
| Sep 30, 2017 | 20.46% |
| Jun 30, 2017 | 19.01% |
| Mar 31, 2017 | 26.75% |
| Dec 31, 2016 | 16.69% |
| Sep 30, 2016 | 16.87% |
| Jun 30, 2016 | 22.69% |
| Mar 31, 2016 | 17.90% |
| Dec 31, 2015 | 43.90% |